Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: standard of care
Drug: dabigatran etexilate

First Posted Date: 2013-07-11

Last Posted Date: 2020-07-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 267

Registration Number: NCT01895777

Locations: 🇦🇷
Hospital General de Niños Pedro de Elizalde, Caba, Argentina
🇧🇪
UZ Leuven, Leuven, Belgium
🇦🇹
AKH - Medical University of Vienna, Wien, Austria

and more 62 locations

Safety and Tolerability of BI 409306 in Patients With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2013-07-04

Last Posted Date: 2024-04-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01892384

Locations: 🇺🇸
1289.18.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ibuprofen (Brufen®)
Drug: Ibuprofen (Nurofen Immedia®)
Drug: Ibuprofen+caffeine FDC

First Posted Date: 2013-06-17

Last Posted Date: 2016-11-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01879371

Locations: 🇩🇪
1335.2.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 187004
Drug: Placebo

First Posted Date: 2013-06-11

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 71

Registration Number: NCT01874483

Locations: 🇩🇪
1307.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: BI 10773
Drug: Empagliflozin

First Posted Date: 2013-06-04

Last Posted Date: 2017-05-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT01867307

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Phase 3

Withdrawn

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 201335
Drug: Telaprevir
Drug: ribavirin
Drug: Pegylated Interferon
Drug: BI 207127

First Posted Date: 2013-05-21

Last Posted Date: 2014-01-23

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01858961

Locations: 🇦🇺
1241.37.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia
🇸🇪
1241.37.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden
🇪🇸
1241.37.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain

and more 9 locations

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3

Active, not recruiting

Conditions: Head and Neck Neoplasms

Interventions: Drug: afatinib
Drug: methotrexate

First Posted Date: 2013-05-17

Last Posted Date: 2024-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 340

Registration Number: NCT01856478

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳
Beijing Chao-Yang Hospital, Beijing, China
🇨🇳
Cancer Hospital of Chinese Academy of Medical Science, Beijing, China

and more 49 locations

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: afatinib

First Posted Date: 2013-05-15

Last Posted Date: 2024-03-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 481

Registration Number: NCT01853826

Locations: 🇮🇹
A.O. Univ. Policlinico "Paolo Giaccone", Palermo, Italy
🇨🇿
University Hospital Ostrava, Ostrava, Czechia
🇮🇱
Rabin Medical Center Beilinson, Petah Tikva, Israel

and more 115 locations

Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients

Completed

Conditions: Hypertension

First Posted Date: 2013-05-15

Last Posted Date: 2015-08-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1674

Registration Number: NCT01853839

Locations: 🇩🇿
Boehringer Ingelheim Investigational Site 109, Algiers, Algeria
🇩🇿
Boehringer Ingelheim Investigational Site 110, Algiers, Algeria
🇩🇿
Boehringer Ingelheim Investigational Site 123, Algiers, Algeria

and more 129 locations

Comparative Effectiveness of Oral Anticoagulants

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2013-05-07

Last Posted Date: 2014-06-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5982

Registration Number: NCT01847547

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy